Patient preferences for features of HER2-targeted treatment of advanced or metastatic breast cancer: a discrete-choice experiment study.

Autor: Mansfield C; RTI Health Solutions, Research Triangle Park, NC, USA. carolm@rti.org., Botha W; RTI Health Solutions, Manchester, UK., Vondeling GT; Daiichi Sankyo Europe, Munich, Germany., Klein K; RTI Health Solutions, Research Triangle Park, NC, USA., Wang K; Daiichi Sankyo Inc, Basking Ridge, NJ, USA., Singh J; Daiichi Sankyo Inc, Basking Ridge, NJ, USA., Hackshaw MD; Daiichi Sankyo Inc, Basking Ridge, NJ, USA.
Jazyk: angličtina
Zdroj: Breast cancer (Tokyo, Japan) [Breast Cancer] 2023 Jan; Vol. 30 (1), pp. 23-35. Date of Electronic Publication: 2022 Sep 08.
DOI: 10.1007/s12282-022-01394-6
Abstrakt: Background: We aimed to quantify patients' benefit-risk preferences for attributes associated with human epidermal growth factor receptor 2 (HER2)-targeted breast cancer treatments and estimate minimum acceptable benefits (MABs), denominated in additional months of progression-free survival (PFS), for given treatment-related adverse events (AEs).
Methods: We conducted an online discrete-choice experiment (DCE) among patients with self-reported advanced/metastatic breast cancer in the United States, United Kingdom, and Japan (N = 302). In a series of nine DCE questions, respondents chose between two hypothetical treatment profiles created by an experimental design. Profiles were defined by six attributes with varying levels: PFS, nausea/vomiting, diarrhea, liver function problems, risk of heart failure, and risk of serious lung damage and infections. Data were analyzed using an error component random-parameters logit model.
Results: Among the attributes, patients placed the most importance on a change in PFS from 5 to 26 months; change from no diarrhea to severe diarrhea was the least important. Avoiding a 15% risk of heart failure had the largest MAB (5.8 additional months of PFS), followed by avoiding a 15% risk of serious lung damage and infections (4.6 months), possible severe liver function problems (4.2 months), severe nausea/vomiting (3.7 months), and severe diarrhea (2.3 months) compared with having none of the AEs. The relative importance of 21 additional months of PFS (increasing from 5 to 26 months) increased for women with HER2-negative disease and those with children.
Conclusions: Patients valued PFS gain higher than the potential risk of AEs when deciding between hypothetical breast cancer treatments.
(© 2022. The Author(s).)
Databáze: MEDLINE
Externí odkaz: